Pharmacokinetic interaction study between the new antiepileptic and CNS drug RWJ-333369 and carbamazepine in healthy adults

被引:27
作者
Chien, Suchean
Bialer, Meir
Solanki, Bhavna
Verhaeghe, Tom
Doose, Dennis R.
Novak, Gerald
Yao, Caiping
机构
[1] Hebrew Univ Jerusalem, Dept Pharmaceut, Sch Med, Fac Med, IL-9120 Jerusalem, Israel
[2] Hebrew Univ Jerusalem, David R Bloom Ctr Pharm, Jerusalem, Israel
[3] Johnson & Johnson Pharmaceut Res & Dev LLC, Raritan, NJ USA
[4] Johnson & Johnson Pharmaceut Res & Dev LLC, Titusville, NJ USA
[5] Johnson & Johnson Pharmaceut Res & Dev, Janssen Pharmaceut NV, Beerse, Belgium
关键词
RWJ-333369; new antiepileptic drug; carbamazepine; pharmacokinetic interaction; healthy subjects;
D O I
10.1111/j.1528-1167.2006.00815.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Purpose: To characterize the possible pharmacokinetic interaction between the new antiepileptic and CNS drug RWJ-333369 and carbamazepine (CBZ) following multiple dosing in healthy subjects. Methods: In an 8-week, open-label, sequential design study, 24 healthy adults received multiple-dose RWJ-333369 alone (5 days 250 mg q12h; 5 days 500 mg q12h), then after a 4-day washout, multiple-dose CBZ alone (3 days 100 mg q12h; 3 days 200 mg q12h; 22 days 300 mg q12h), and then combination of CBZ (300 mg q12h), and RWJ-333369 (5 days 250 mg q12h; 5 days 500 mg q12h). Results: At steady-state following multiple dosing, RWJ-333369 peak plasma concentration (C-max) and area under the concentration-time-curve within the dosing interval (AUCss) increased in proportion to dose. The C-max and AUCss of CBZ were similar when given alone or concomitantly with RWJ-333369. The 90% confidence intervals for the ratio of CBZ C-max and AUCss with/without RWJ-333369 were: 94-104% and 95-104%, respectively (well within the equivalence range of 80-125%). When RWJ-333369 was administered with CBZ, its mean (SD) oral clearance increased from 3.2 L/h to 4.9 L/h and consequently its mean half-life was shortened from 10.4 (1.9) h to 7.4 (1.2) h, and mean AUCss and C-max were reduced by 37% and 30%, respectively. Conclusions: There was no effect of multiple-dose RWJ-333369 on CBZ pharmacokinetics. CBZ induced RWJ-333369 clearance, resulting in shortened half-life and decreased exposure (AUCss) and C-max. Concomitant administration of RWJ-333369 with CBZ was generally safe and tolerated.
引用
收藏
页码:1830 / 1840
页数:11
相关论文
共 15 条
[1]   Lack of effect of St John's Wort on carbamazepine pharmacokinetics in healthy volunteers [J].
Burstein, AH ;
Horton, RL ;
Dunn, T ;
Alfaro, RM ;
Piscitelli, SC ;
Theodore, W .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 68 (06) :605-612
[2]  
Chien SC, 2005, EPILEPSIA, V46, P181
[3]  
Grabenstatter HL, 2004, EPILEPSIA, V45, P197
[4]  
KASTELEIJNNOLST.DG, 2004, 10 EIL C NEW ANT DRU
[5]   Complexities of glucuronidation affecting in vitro-in vivo extrapolation [J].
Lin, JH ;
Wong, BK .
CURRENT DRUG METABOLISM, 2002, 3 (06) :623-646
[6]  
MANNENS GSJ, IN PRESS ADSORPTION
[7]   Serum concentrations of lamotrigine in epileptic patients: The influence of dose and comedication [J].
May, TW ;
Rambeck, B ;
Jurgens, U .
THERAPEUTIC DRUG MONITORING, 1996, 18 (05) :523-531
[8]   Lack of effect of citalopram on the steady-state pharmacokinetics of carbamazepine in healthy male subjects [J].
Moller, SE ;
Larsen, F ;
Khan, AZ ;
Rolan, PE .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2001, 21 (05) :493-499
[9]  
Nehlig A, 2005, EPILEPSIA, V46, P215
[10]  
PELLOCK JM, 2002, ANTIEPILEPTIC DRUGS, P301